M&A · Healthcare · Pharmaceutical Preparations
Ipsen, S.A. to acquire Albireo Pharma, Inc.
Announced Jan 9, 2023 · Closed Mar 2, 2023
Deal value$952MEV $667M
Premium84.0%To unaffected price
EV / Adj. EBITDA—11.6x EV / Revenue
ConsiderationAll cash$42.00 per share
Transaction
- Acquirer
- Ipsen, S.A.
- Target
- Albireo Pharma, Inc.
- Buyer type
- Strategic
- Offer price per share
- $42.00
- Enterprise value
- $667M
- Status
- Closed Mar 2, 2023
Deal protections
- Break fee (target pays)
- $36.0M · 3.8%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Goldman Sachs
- To the target
- Centerview
Sector context · Healthcare
- Comparable deals
- 73 in the prior 24 months
- Premium
- 84.0% vs. 50.0% sector median
- EV / Adj. EBITDA
- Sector median 21.5x
- Break fee
- 3.8% vs. 3.4% sector median
Timeline
- AnnouncedJan 9, 2023
- Tender offerJan 23, 2023
- ClosedMar 2, 2023